BIIB vs PYXS · P/E 21, rev $9.89B vs rev $2.8M
Biogen Inc (BIIB) versus Pyxis Oncology Inc (PYXS) — a side-by-side from cached financials, not a winner call.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ. It is led by Christopher A. Viehbacher.
Pyxis Oncology Inc (PYXS) is a biotechnology company listed on NASDAQ.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Latest reported PYXS revenue for 2025-09-30 was $2.8M. Net income was -$22.0M. Revenue was up 0.0% from 2025-06-30 to 2025-09-30. PYXS currently screens at market cap $109.6M.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. PYXS currently screens at market cap $109.6M.
Not investment advice. Open the BIIB and PYXS stock pages for the full models.
Not investment advice.